$1.71 Billion is the total value of Camber Capital Management LP's 48 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)adr | $120,398,000 | +1.9% | 2,250,000 | +25.0% | 7.05% | -7.7% |
| MYL | Buy | MYLAN NV | $85,748,000 | +26.9% | 1,850,000 | +48.0% | 5.02% | +14.9% |
| MDCO | Buy | MEDICINES COMPANY | $79,425,000 | -3.3% | 2,500,000 | +13.6% | 4.65% | -12.4% |
| BKD | Buy | BROOKDALE SENIOR LIVING | $79,400,000 | +91.2% | 5,000,000 | +122.2% | 4.65% | +73.2% |
| NUVA | Buy | NUVASIVE INC. | $72,975,000 | +22.6% | 1,500,000 | +36.4% | 4.27% | +11.1% |
| STJ | New | ST. JUDE MEDICAL, INC. | $68,750,000 | – | 1,250,000 | +100.0% | 4.03% | – |
| SEM | Buy | SELECT MEDICAL HOLDINGS CORP | $65,841,000 | +22.8% | 5,575,000 | +23.9% | 3.86% | +11.3% |
| LIVN | LIVANOVA PLC | $64,776,000 | -9.1% | 1,200,000 | 0.0% | 3.79% | -17.6% | |
| OFIX | ORTHOFIX INTL N V | $62,280,000 | +5.9% | 1,500,000 | 0.0% | 3.65% | -4.1% | |
| NKTR | Buy | NEKTAR THERAPEUTICS | $61,875,000 | +4.9% | 4,500,000 | +28.6% | 3.62% | -4.9% |
| GHDX | GENOMIC HEALTH INC | $60,887,000 | -29.6% | 2,458,100 | 0.0% | 3.57% | -36.2% | |
| LDRH | Buy | LDR HOLDING CORP | $57,353,000 | +328.2% | 2,250,000 | +321.8% | 3.36% | +287.9% |
| TEVA | New | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)call | $53,510,000 | – | 1,000,000 | +100.0% | 3.13% | – |
| VRX | New | VALEANT PHARMACEUTICALS INT (USA) | $52,600,000 | – | 2,000,000 | +100.0% | 3.08% | – |
| ABBV | New | ABBVIE INC | $51,408,000 | – | 900,000 | +100.0% | 3.01% | – |
| GILD | New | GILEAD SCIENCES, INC.call | $45,930,000 | – | 500,000 | +100.0% | 2.69% | – |
| BIIB | New | BIOGEN IDEC INC | $45,556,000 | – | 175,000 | +100.0% | 2.67% | – |
| THC | TENET HEALTHCARE CORP | $43,395,000 | -4.5% | 1,500,000 | 0.0% | 2.54% | -13.5% | |
| DGX | QUEST DIAGNOSTICS INC | $42,870,000 | +0.4% | 600,000 | 0.0% | 2.51% | -9.0% | |
| New | CARDIOVASCULAR SYSTEMS INC | $42,517,000 | – | 4,100,000 | +100.0% | 2.49% | – | |
| UAM | UNIVERSAL AMERICAN CORPORATION | $41,948,000 | +2.0% | 5,875,000 | 0.0% | 2.46% | -7.6% | |
| MASI | MASIMO CORPORATION | $41,840,000 | +0.8% | 1,000,000 | 0.0% | 2.45% | -8.7% | |
| ALKS | New | ALKERMES INC | $41,028,000 | – | 1,200,000 | +100.0% | 2.40% | – |
| MDVN | New | MEDIVATION INC. | $37,934,000 | – | 825,000 | +100.0% | 2.22% | – |
| ARIA | ARIAD PHARMACEUTICALS INC | $34,539,000 | +2.2% | 5,405,235 | 0.0% | 2.02% | -7.3% | |
| ELGX | New | ENDOLOGIX INC | $32,307,000 | – | 3,864,500 | +100.0% | 1.89% | – |
| NVTA | Buy | INVITAE CORP | $28,098,000 | +69.0% | 2,746,622 | +35.6% | 1.64% | +53.2% |
| SQNM | Buy | SEQUENOM INC COM | $24,428,000 | -13.7% | 17,325,000 | +0.4% | 1.43% | -21.8% |
| WMGI | New | WRIGHT MEDICAL GROUP NV | $24,113,000 | – | 1,452,600 | +100.0% | 1.41% | – |
| New | ARENA PHARMACEUTICALS INC | $20,685,000 | – | 10,500,000 | +100.0% | 1.21% | – | |
| OSUR | ORASURE TECHNOLOGIES INC | $14,460,000 | +12.3% | 2,000,000 | 0.0% | 0.85% | +1.8% | |
| AMAG | New | AMAG PHARMACEUTICALS | $14,040,000 | – | 600,000 | +100.0% | 0.82% | – |
| BIOS | Buy | BIOSCRIP INC | $13,225,000 | +26.0% | 6,180,000 | +3.0% | 0.77% | +14.0% |
| PLX | PROTALIX BIO THERAPEUTICS, INC | $11,158,000 | -17.6% | 13,275,000 | 0.0% | 0.65% | -25.4% | |
| ELOS | SYNERON MEDICAL LTD | $11,007,000 | -5.2% | 1,505,700 | 0.0% | 0.64% | -14.0% | |
| INNOCOLL AG | $9,533,000 | +3.4% | 1,111,111 | 0.0% | 0.56% | -6.4% | ||
| DRRX | DURECT CORP COM | $8,100,000 | -38.9% | 6,000,000 | 0.0% | 0.47% | -44.7% | |
| BIOL | BIOLASE INC | $6,985,000 | +55.7% | 5,332,394 | 0.0% | 0.41% | +41.0% | |
| PROTALIX BIO THERAPEUTICS, INCnote 4.500% 9/1 | $6,000,000 | -1.2% | 9,000,000 | 0.0% | 0.35% | -10.7% | ||
| PTCT | Buy | PTC THERAPEUTICS | $5,757,000 | -64.5% | 893,900 | +78.8% | 0.34% | -67.8% |
| CATB | CATABASIS PHARMACEUTICALS INC | $5,040,000 | -36.4% | 1,000,000 | 0.0% | 0.30% | -42.4% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS | $4,970,000 | -12.9% | 1,847,500 | 0.0% | 0.29% | -21.1% | |
| GNMK | GENMARK DIAGNOSTICS | $3,421,000 | -32.1% | 649,097 | 0.0% | 0.20% | -38.5% | |
| CRDC | New | CARDICA INC | $2,981,000 | – | 837,483 | +100.0% | 0.18% | – |
| ANGO | ANGIODYNAMICS INC. | $2,989,000 | +1.3% | 243,183 | 0.0% | 0.18% | -8.4% | |
| UNIS | UNILIFE CORP | $1,870,000 | +37.3% | 2,750,000 | 0.0% | 0.11% | +25.0% | |
| TARGACEPT INCnote | $1,685,000 | 0.0% | 1,684,799 | 0.0% | 0.10% | -9.2% | ||
| BIOLASE INCcall | $22,000 | +46.7% | 1,841,173 | 0.0% | 0.00% | 0.0% | ||
| XLV | Exit | SELECT SECTOR SPDR TRput | $0 | – | -16,700 | -100.0% | -0.08% | – |
| CRDC | Exit | CARDICA INC | $0 | – | -8,374,846 | -100.0% | -0.08% | – |
| Exit | ARENA PHARMACEUTICALS INC | $0 | – | -10,500,000 | -100.0% | -1.29% | – | |
| BMY | Exit | BRISTOL MYERS SQUIBB COput | $0 | – | -500,000 | -100.0% | -2.22% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -300,000 | -100.0% | -2.40% | – |
| Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -2,575,000 | -100.0% | -2.52% | – | |
| MJN | Exit | MEAD JOHNSON NUTRITION CO | $0 | – | -500,000 | -100.0% | -2.55% | – |
| Exit | REGENERON PHARMACEUTICALS INCput | $0 | – | -100,000 | -100.0% | -3.51% | – | |
| HCA | Exit | HCA HOLDINGS INC | $0 | – | -1,000,000 | -100.0% | -4.37% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -2,000,000 | -100.0% | -4.39% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -500,000 | -100.0% | -6.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.